<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="1" offset="0" totalResults="1"><SearchResults><Trial Id="35785"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytosine DNA methyltransferase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cancer Research UK</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2010-11-01T00:00:00Z</DateEnd><DateStart>2007-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000613805</Identifier><Identifier>CRUK-PH2/051</Identifier><Identifier>CTA-21106/0219/001</Identifier><Identifier>Decitabine and Carboplatin in Relapsed Ovarian Cancer</Identifier><Identifier>EUDRACT-2006-002324-41</Identifier><Identifier>MGI-CRUK-PH2/051</Identifier><Identifier>NCT00514124</Identifier><Identifier>NCT00748527</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspnea</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>carboplatin alone</Intervention><Intervention>Variable regimens including carboplatin , carboplatin + decitabine , decitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>134</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Safety Issues</Reason></ReasonForTrialDiscontinuation><Teaser>This randomized, phase II trial was studying carboplatin and decitabine to see how well they work compared with carboplatin alone in treating patients with progressive, advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints - Assessment of genetic marker</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Decitabine and Carboplatin in Relapsed Ovarian Cancer: Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Ovarian Cancer Subjects with CA-125 Expression</PatientSegment><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Sensitive Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CA-125 antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Stanley B. Kaye, MD, FRCP</Name><Name>Stanley Kaye</Name></ContactNames></Trial></SearchResults></trialResultsOutput>